Schedule III substances, which include Tylenol with codeine, ketamine and anabolic steroids, have a low to moderate potential for physical and psychological dependence, according to the DEA. Conversely, Schedule I drugs, such as heroin and LSD, have a high potential for abuse and no accepted medical use. Credit: Skyliz/Adobe Stock
In a letter to the Drug Enforcement Administration, the Department of Health & Human Services has recommended moving marijuana from a Schedule I to Schedule III substance under the Controlled Substance Act.
Cannabis trade publications are heralding the move as historic, as it would allow for more robust research on marijuana, and could make insurers and financial services providers more willing to work with these businesses.
Want to continue reading?
Become a Free PropertyCasualty360 Digital Reader
Your access to unlimited PropertyCasualty360 content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking insurance news and analysis, on-site and via our newsletters and custom alerts
- Weekly Insurance Speak podcast featuring exclusive interviews with industry leaders
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the employee benefits and financial advisory markets on our other ALM sites, BenefitsPRO and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Steve Hallo
Steve Hallo is managing editor of PropertyCasualty360.com. He can be reached at [email protected]
